González GT, Vivas BL, González TM

Language: Spanish
References: 13
Page: 320-328
PDF size: 187.03 Kb.

ABSTRACT

Introduction: HIV morbidity and mortality has substantially decreased with the use of HAART. The prevalence of lipodystrophy in HAART patients is greatly variable; clinically, thechanges may be subtle at the beginning, with signs of central lipohypertrophy and peripheral lipoatrophy in early stages. When lipoatrophy affects the face and/or fat accumulates to the cervicodorsal region (buffalo hump), this is considered advanced lipodystrophy.
Clinical case: female patient of black race, 43 years of age, diagnosed HIVpositive in July 1999. After several years of treatment, changes started to be noticed in her body constitution, with clear signs of lipodystrophy.
Conclusions: the syndrome of lipodystrophy constitutes an adverse effect of HAART in AIDS patients, causing morphological and metabolic alterations that affects adherence to the treatment. Aesthetic repercussions provoke psychological alterations that affect these individuals directly in the affective, social and working areas. More research is needed for more evidence about this syndrome. The proper evaluation by health care professionals of HIV patients consuming HAART is vitally important, in order to timely diagnose the syndrome of lipodystrophy and apply fitting methods of treatments.

REFERENCES

1. Viñas Martínez AL, Oliva Venereo DC, Noda Ortega L, Rios López N, Cáceres Rodríguez D, Herrera Wainshtok AC, et al. Características clínico epidemiológicas de las personas con VIH/SIDA en el municipio Arroyo Naranjo 2008. Rev haban cienc méd. 2012 Mar; 11(1).

2. Colectivo de Autores. Pautas para la Atención Integral al paciente con infección por VIH/sida en Cuba. Ministerio de Salud Pública de Cuba. Programa Nacional de Prevención y Control de las its/vih-sida. Dirección Nacional de Asistencia Médica; 2009.

3. Machado Gonçalves Soares F, Carvalho Costa IM. Lipoatrofia facial associada ao HIV/AIDS: do advento aosconhecimentos atuais. An. Bras. Dermatol. Sept/Oct.2011;86(5).

4. Fernández Argüelles RA, Gutiérrez Rentería CC, Castro Melchor P, Flores García A, Cancino Marentes ME. Síndrome de lipodistrofia en pacientes con VIH/sida que reciben terapia antirretroviral de gran actividad en Tepic, México. Rev Cubana Farm. 2012 Jun; 46(2).

5. Ciencias de salud de la Universidad de Nuevo México. Lipodistrofia (Cambios en la Forma del Cuerpo). 2012.

6. Castro Sansores C, Santos Rivero A, Salazar Rendón JC, Díaz Rodríguez I, Góngora Biachi R, González Martínez P, et al. Síndrome de lipodistrofia en pacientes con infección por VIH que reciben tratamiento antirretroviral. Med Int Mex. 2008; 24(1).

7. Castelar Tsuda L, Machado da Silva M, Artioli Machado A, Morais Fernandes AP. Body changes: antiretroviral therapy and lipodystrophy syndrome in people living with HIV/aids. Rev. Latino-Am. Enfermagem. Sept./Oct.2012; 20(5).

8. EACS (European AIDS Clinical Society).Lipodistrofia: prevención y tratamiento. En: Guías clínicas Versión 6.1. nov 2012.

9. VII Conferencia de la IAS sobre patogénesis. Tratamiento y prevención del VIH. Kuala Lumpur: Malasia; 2013 Mar 06.

10. Resino S. Síndrome metabólico y lipodistrofia producida por el tratamiento antirretroviral en pacientes infectados por VIH-1. 2013.

11. Mallewa JE, Wilkins E, Vilar J, Macpherson M, Dominic DD, Munir Pirmohamed. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. Journal of Antimicrobial Chemotherapy. June 2008; 62.

12. Mota SegattoI F, Forte Freitas J, Ribeiro dos Santos V, Pinto Alves KC, Aparecida Barbosa D, Martins Portelinha FA, et al. Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy. Rev. Soc. Bras. Med. Trop. Uberaba. July/Aug 2011; 44(4).

13. Viega Juchem GM, Ramos Lazzarotto A. Treinamento físico na síndrome lipodistrófica: revisão sistemática. Rev Bras Med Esporte. July/Aug.2010; 16(4):